Southland Equity Partners’s CervoMed CRVO Stock Holding History

Southland Equity Partners’s Portfolio CRVO Stock Details CRVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-160	Closed	-$9.56K	–	149
2020 Q4	$9.56K	Buy	+160	New	+$9.37K	0.01%	126

Other funds holding CRVO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Yu Fan $97M AUM 57.2% 1-Year Est. Return

Southland Equity Partners's CRVO Position: Q1 2021 in Review

Southland Equity Partners sold out of CervoMed (CRVO) in Q1 2021, closing a stake of 160 shares — an estimated $9.56K sold.

Southland Equity Partners first reported a position in CRVO in Q4 2020 and held it in 1 quarter. The position peaked at $9.56K in Q4 2020. 22 funds tracked by Wall St. Rank hold CRVO as of Q1 2021.

Southland Equity Partners reported no remaining CervoMed position as of Q1 2021 after selling out during the quarter.
Southland Equity Partners sold 160 CervoMed shares in Q1 2021, an estimated $9.56K.
Southland Equity Partners first reported a position in CervoMed in Q4 2020 and held it in 1 quarter.
Southland Equity Partners's CervoMed position peaked at $9.56K in Q4 2020.
22 funds tracked by Wall St. Rank held CervoMed as of Q1 2021.

Based on Southland Equity Partners's 13F filing for Q1 2021, filed 2 Jan 2024.